Lykos Therapeutics' new drug application for MDMA plus psychiatric intervention for adults with PTSD will be the first reviewed by an FDA committee for such a therapy.
New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.
Lykos Therapeutics announced the FDA accepted its NDA for MDMA-assisted therapy for individuals with PTSD on February 9, 2024, backed by phase 3 data showing the drug’s efficacy.